Evogene Announces Acute Graft-Versus-Host Disease (aGVHD) as the Target Indication for Its Internal AI-Driven Drug Discovery Program
Evogene named acute graft-versus-host disease (aGVHD) as the target indication for its internal AI-driven drug discovery program, aiming at a potential first-in-class small molecule for steroid-refractory patients. In several months the company generated novel, patentable small-molecule candidates with nanomolar potency, using its ChemPass AI platform to screen a virtual space of more than 110 billion molecules, with input from aGVHD experts at Dana-Farber and University Medical Center Freiburg.
Key figures
- Virtual chemical space
- more than 110 billion molecules
- Steroid refractory mortality
- up to 50%
- Transplant recipients affected
- 30%-40%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.